Table 1.

Patient demographics.

Sex	Age (years)	F-calpro (μg/g)	UC/CD	Endoscopic diagnosis	Medication	Severity of the disease during the 3-year follow-up
F	39	> 2000	UC	proctitis	prednisolone + azathioprine 150 mg	severe
F	19	1400	UC	pancolitis	methylprednisolone + azathioprine 25 mg × 2 + 5-ASA 1600 mg × 2	severe
F	28	> 2000	UC	pancolitis	prednisolone + 5-ASA 1600 mg × 2	mild/moderate
M	27	> 2000	CD	jejunitis, ileitis	methylprednisolone	severe
F	19	> 2000	UC	pancolitis	prednisolone + 5-ASA 1600 mg × 2	severe
F	19	> 2000	I	pancolitis	methylprednisolone + 5-ASA 2 g + 1 g	severe
F	31	> 2000	UC	pancolitis	methylprednisolone + azathioprine 150 mg + 5-ASA 1600 mg × 2	severe
F	30	1294	CD	ileitis, sigmoiditis	methylprednisolone + azathioprine 25 mg × 2	mild/moderate
F	36	393	CD	ileitis	prednisolone + mercaptopurine 50 mg × 1	mild/moderate
F	54	557	CD	ileitis	budesonide 9 mg × 1 + azathioprine 25 mg × 1	mild/moderate
M	37	5860	UC	pancolitis	prednisolone + azathioprine 25 mg × 2	severe
F	19	3178	CD	ileitis, segmental colitis	methylprednisolone	mild/moderate
F	85	45	CD	Segmental colitis	budesonide 9 mg × 1	mild/moderate
M	79	607	CD	jejunitis, ileitis	budesonide 9 mg × 1	mild/moderate

F, Female, M, Male, F-calpro, Fecal calprotectin, UC, Ulcerative colitis, CD, Crohn’s disease, I, Intermediate colitis. The medication is described at beginning the of the diagnosed relapse. The dose of intravenous methylprednisolone was 40 + 20 mg per day (for the hospitalized patients), and the dose of per oral prednisolone (for the patients at outpatient clinic) was 40 mg per day and the cut down of prednisolone was − 5 mg per week consecutively. The dose of oral budesonide was 9 mg per day at the time of relapse and the cut down of the dose was − 3 mg per month consecutively. 5-ASA = 5-aminosalicylic acid. All the parameters besides the severity of the disease are described at the time of enrollment. The severity of the disease is described during the 3-year follow up.